While clinical trials have evolved and improved over time, fundamental changes are needed to reflect the outcomes of great relevance to the institutions where they are performed, by integrating scientific rationale and society's movement to increase efficiency, accountability, and transparency by fast integrating the next-generation advances offered by omics technology and artificial intelligence. Several global clinical and exploratory collaborative studies that achieved successful outcomes in terms of patients' survival, drug toxicity, efficacy, safety, biomarkers, and consensus reached to improve good clinical practices are addressed in this article. Going forward, through collaborations, cooperation, and intellectual curiosity many more advances can be made in clinical trial approaches that can bring transparency, accountability, best outcomes, and develop friendship with trust among all the involved.
Keywords: ADTree; APHINITY CREATE-X; BEATRICE; BIG; BOLERO-3; Biomarker; Breast cancer; Clinical trial paradigm; Collaboration; Deep Mind; EBCTCG; FALCON; Hanover; KBCCC; NSABP; Next generation; Toxicity; Watson.